ClinicalTrials.gg
Status unknownNCT04341025PRIMEDUpdated Oct 19, 2022

Providing Insight Into and Mindfulness for Situational Erectile Dysfunction

An interventional study of Mindfulness based psychosexual therapy ( MBPST) in Situational Erectile Dysfunction, sponsored by Vancouver Coastal Health. Status unknown at 1 site in Canada. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-10-19.

Sponsored by Vancouver Coastal Health · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
19 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Erectile Dysfunction with a site in Canada — 5 open to participants now, 5 under way, none of them phase 3. Erectile Dysfunction · Canada.

Planned enrollment
19th of 27
60 · median 120
Started
2020
the only one that year
No phase
5 of 29
2 open now
Registered
24th of 29
by date

Among the 29 studies in Erectile Dysfunction with a site in Canada, this one is the 19th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2020, is one of 5 with no phase, and was the 24th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

5 of the 29 studies in Erectile Dysfunction with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 19 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Erectile Dysfunction with a site in Canada, or all of them as a file.
02

Study summary

Erectile dysfunction (ED) is among the most common sexual dysfunctions experienced by men, affecting at least one third of men across the lifespan. Although pharmacological treatments are available, adherence to these treatments is poor, suggesting the need for integration of psychological interventions. This study will determine if a 6-session mindfulness-based psychosexual therapy (MBPST) group will be effective and feasible for men with situational ED. This study is adapted from a previously published 4-session MBPST protocol which was found to be beneficial for men with situational ED. Outcomes are measured using self-report questionnaires on sexual functioning/enjoyment, relationship satisfaction, and treatment acceptability.

Read the detailed description

PURPOSE The purpose of this study is to assess the feasibility and efficacy of a 6-session mindfulness-based psychosexual therapy (MBPST) treatment protocol using self-report questionnaires. The current protocol is adapted from a pre-existing 4-session mindfulness-based psychosexual therapy (MBPST) protocol from a pilot study which has already demonstrated benefits in the treatment of situational erectile dysfunction (ED). The six sessions include elements of psychoeducation, cognitive therapy, mindfulness training, and sex therapy techniques. The elements comprising the six sessions are evidence-based, as their effectiveness has been demonstrated in female samples (e.g., Brotto et al., 2012; Paterson et al., 2017), and more recently in the context of a four-session pilot in men with situational ED (H15-03172; published in Bossio et al., 2018). The rationale for an increase from a 4 to 6-session approach came from qualitative analysis of participant perspectives in the pilot study and from investigator experience.

HYPOTHESES

  1. Men who undergo MBPST treatment will show significant post-treatment improvements at follow-up (immediately following treatment and at 1- and 4-months after treatment completion), compared to baseline, to primary endpoints of: (i) erectile functioning; (ii) sexual distress; (iii) sexual satisfaction and pleasure.
  2. Men who undergo MBPST treatment will show significant post-treatment improvements at follow-up (immediately following treatment and at 1- and 4-months after treatment completion), compared to baseline, to secondary endpoints of: (i) psychological variables/mental status (i.e., anxiety); (ii) mindfulness-related variables; and (iii) relationship satisfaction. The role of secondary endpoints as mediators to primary endpoints of sexual functioning will also be assessed.
  3. Men will report significantly less use of medications for ED (i.e., PDE5 inhibitors and intracavernosal injections) at 4-month follow-up compared to pre-treatment.

JUSTIFICATION Sexual dysfunction affects at least one third of men across the lifespan (Laumann, Paik, \& Rosen, 1999), and can have significant impact on quality of life and on intimate relationships (Hatzimouratidis et al., 2010). Erectile dysfunction (ED), or the inability to attain and/or maintain an erection sufficient for satisfactory sexual activity (NIH, 1993), is among the most common sexual dysfunctions experienced by men. The aetiology of ED is complex and can result from a variety of physiological (e.g., age, cardiovascular health, medication use), psychological (e.g., anxiety), and lifestyle factors (e.g., smoking status; Nicolosi, Moreira, Shirai, Tambi, \& Glasser, 2003). Situational ED refers to ED that occurs in certain contexts (e.g., with a partner), but not others (e.g., masturbation, nocturnal erections).

Although pharmacological interventions (i.e., PDE5 inhibitors) have been available to treat ED since the 1990's, adherence to these treatments is poor, with approximately 50% of men failing to re-fill their first prescription (Carvalheira, Pereira, Maroco, \& Forjaz, 2012; Hanash, 1997), despite the restoration of erections (Giannitsas, Konstantinopoulos, Patsialas, \& Perimenis, 2008). This low adherence to pharmacological treatments suggests that there are aspects of ED, beyond the rigidity of erections that are not being addressed by medications. This may be particularly true in the case of situational ED, where psychogenic factors are playing a major role (McCabe et al., 2016).

There is increasing evidence documenting the benefits of MBCT for women with sexual dysfunction (Brotto, Basson, \& Luria, 2008; Brotto et al., 2008; Brotto et al., 2012; Brotto, Seal, \& Rellini, 2012; Brotto \& Basson, 2014; Paterson, Handy, \& Brotto, 2017). Further, the investigators recently adapted a pre-existing 4-session MBPST protocol, which had already been shown to be effective in the treatment of female sexual dysfunction, to fit the needs of men with situational ED and pilot-tested it in group format (H15-03172). Our pilot data suggest significant benefits for men with situational ED (Bossio, Basson, Driscoll, Correia, \& Brotto, 2019). However, feedback from the pilot participants indicated a need for additional sessions as they had only begun to establish a regular mindfulness practice. Mindfulness-based interventions consisting of eight sessions are common and have been shown to be effective in reducing depressive symptoms (Sipe \& Eisendrath, 2012), depressive relapse (Teasdale, Segal, Williams, Ridgeway, Soulsby, \& Lau, 2000), and anxiety (Evans, Ferrando, Findler, Stowell, Smart, \& Haglin, 2008). However, the investigators were skeptical about the willingness and ability of patients to commit to eight consecutive weeks of treatment. Therefore, the current project is a pilot study intended to assess the feasibility and efficacy of a 6-session MBPST program for situational ED.

OBJECTIVES The main objective of this study is to test the feasibility and efficacy of a 6-session MBPST protocol for men with situational ED. Specifically, the investigators hope to find that men who undergo this treatment will experience improvements in primary (e.g., decreased erectile dysfunction and sexual distress), and secondary endpoints (e.g., increased relationship satisfaction and mental well-being). Further, the investigators hope to find that gains in the primary and secondary endpoints are maintained at 1- and 4-months.

RESEARCH DESIGN Participants (N=60) will take part in a 6-session MBPST group (n=6-10) for treatment of situational ED, either in-person or in an online format. Each session will be 2 hours in length and will be spaced one week apart, for a total of 12 hours of treatment time. Participants will also take part in supportive group follow-up sessions at 1- and 4-months following group completion where participants are free to share their experiences with the group, ask questions, and participate in troubleshooting. Treatment endpoints will be assessed at four time-points (pre-treatment (Time 1), immediate post-treatment (Time 2), 1-month post-treatment (Time 3), and 4-months post-treatment (Time 4)).

STATISTICAL ANALYSIS One-way repeated-measures multivariate analysis of variance (MANOVA) will be used to assess our primary hypothesis-that men will show improvements in primary (i.e., sexual functioning) endpoints following treatment-with the primary endpoint measures as the dependent variables (e.g., ED severity, sexual distress, sexual satisfaction, pleasure), time-point (pre-treatment, immediate post-treatment, 1-month post-treatment, and 4-months post-treatment) as the independent variable, and age as a covariate.

Our secondary hypotheses-that men will show improvements secondary endpoints (i.e., mindfulness-related variables, mental status, and relationship factors) following treatment-will also be examined using the same repeated-measures MANOVA strategy described above. The hypothesis that secondary endpoints act as mediators of sexual functioning following treatment will also be examined using repeated-measures ANOVAs with primary endpoint measures as the dependent variable (i.e., sexual functioning), time-point (pre-treatment, immediate post-treatment, 1-month post-treatment, and 4-months post-treatment) as the independent variable, and secondary endpoints (e.g., change in relationship satisfaction) as mediators.

Our tertiary hypothesis-that men will report using medications for ED significantly less 4-months after treatment conclusion compared with pre-treatment use-will be assessed using paired-sample t-tests comparing frequency of use and dose before treatment and 4-months after treatment.

03

Conditions studied

  • Situational Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

This study is open to individuals who are:

  • Diagnosed with situational erectile dysfunction (ED) of at least 6 months duration, as assessed by a physician at the BC Centre for Sexual Medicine according to criteria
  • 19 years of age or older
  • Fluent enough in English to participate in group
  • Willing to abstain from using medications for ED (i.e., PDE5 inhibitors, intracavernosal injections, MUSE etc.) from the start of treatment until the 1-month follow-up (totaling 10 weeks)
  • Comfortable and interested in participating in a small group format with 6-10 others

Exclusion criteria

Exclusion Criteria:

This study is not suitable for individuals who:

  • Do not experience an exacerbation of ED in the partnered context
  • Have a current unmanaged health condition (e.g., unmanaged diabetes mellitus) or unstable mental health condition (e.g., severe depression/anxiety, active suicidal ideation) that would interfere with self- or partnered-sexual activities or with group participation
  • Do no feel comfortable participating in a small group format with 6-10 others
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Single Arm

    Patients are compared to themselves before and after the treatment.

    Behavioral: Mindfulness based psychosexual therapy ( MBPST)

Interventions

  • BehavioralMindfulness based psychosexual therapy ( MBPST)

    The group treatment sessions will integrate empirically supported elements of psychoeduation, cognitive behavioural therapy, and mindfulness skills. Each of the six sessions will follow the well-defined manualized treatment protocol. The treatment is adapted from the study team's previous mindfulness-based treatment group (H15-03172), for situational ED which has been shown to be effective. Participants will be provided with handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and/or behavioural exercises between sessions. During the 2 follow-up sessions, participants will be invited to share their experience since the conclusion of group, ask questions, and participate in troubleshooting.

    Also known as: MBCT ( Mindfulness based cognitive therapy )

06

What researchers measure

Primary outcomes

  1. Self-reported Erectile Functioning as measured by International Index of Erectile Function - 5

    (IIEF-5; Rosen, Cappelleri, Smith, Lipsky, \& Pena, 1999); 5 item questionnaire

    Time frame: Change from baseline to immediately post treatment (6 weeks)

  2. Self-reported Erectile Functioning as measured by International Index of Erectile Function - 5

    (IIEF-5; Rosen, Cappelleri, Smith, Lipsky, \& Pena, 1999); 5 item questionnaire

    Time frame: Change from baseline to one month post-treatment (10 weeks)

  3. Self-reported Erectile Functioning as measured by International Index of Erectile Function - 5

    (IIEF-5; Rosen, Cappelleri, Smith, Lipsky, \& Pena, 1999); 5 item questionnaire

    Time frame: Change from baseline to four months post-treatment (22 weeks)

  4. Self-reported Sexual Distress as measured by Sexual Distress Scale-Revised

    (Derogatis, Clayton, Lewis-D'Agostino, Wunderlich, \& Fu, 2008). This scale was recently validated for measuring sexual distress in men (Santos-Iglesias, Mohamed, Danko, \& Walker, 2018); 13 item rating scale

    Time frame: Change from baseline to immediately post treatment (6 weeks)

  5. Self-reported Sexual Distress as measured by Sexual Distress Scale-Revised

    (Derogatis, Clayton, Lewis-D'Agostino, Wunderlich, \& Fu, 2008). This scale was recently validated for measuring sexual distress in men (Santos-Iglesias, Mohamed, Danko, \& Walker, 2018); 13 item rating scale

    Time frame: Change from baseline to one month post-treatment (10 weeks)

  6. Self-reported Sexual Distress as measured by Sexual Distress Scale-Revised

    (Derogatis, Clayton, Lewis-D'Agostino, Wunderlich, \& Fu, 2008). This scale was recently validated for measuring sexual distress in men (Santos-Iglesias, Mohamed, Danko, \& Walker, 2018); 13 item rating scale

    Time frame: Change from baseline to four months post-treatment (22 weeks)

  7. Self-reported Confidence in Sexual and Erectile Competence as measured by Sexual Self-Efficacy Scale - Erectile Functioning

    (Fichten, Spector, Amsel, Creti, Brender, \& Libman, 1998), which measures confidence in sexual and erectile competence; 25 item rating scale

    Time frame: Change from baseline to immediately post treatment (6 weeks)

  8. Self-reported Confidence in Sexual and Erectile Competence as measured by Sexual Self-Efficacy Scale - Erectile Functioning

    (Fichten, Spector, Amsel, Creti, Brender, \& Libman, 1998), which measures confidence in sexual and erectile competence; 25 item rating scale

    Time frame: Change from baseline to one month post-treatment (10 weeks)

  9. Self-reported Confidence in Sexual and Erectile Competence as measured by Sexual Self-Efficacy Scale - Erectile Functioning

    (Fichten, Spector, Amsel, Creti, Brender, \& Libman, 1998), which measures confidence in sexual and erectile competence; 25 item rating scale

    Time frame: Change from baseline to four months post-treatment (22 weeks)

  10. Self-reported Sexual Satisfaction and Pleasure as measured by International Index of Erectile Function - Overall Satisfaction Subscale.

    (Rosen, Riley, Wagner, Osterloh, Kirkpatrick, \& Mishra, 1997), which measures sexual satisfaction. 2-item questionnaire

    Time frame: Change from baseline to immediately post treatment (6 weeks)

  11. Self-reported Sexual Satisfaction and Pleasure as measured by International Index of Erectile Function - Overall Satisfaction Subscale

    (Rosen, Riley, Wagner, Osterloh, Kirkpatrick, \& Mishra, 1997), which measures sexual satisfaction. 2-item questionnaire

    Time frame: Change from baseline to one month post-treatment (10 weeks)

  12. Self-reported Sexual Satisfaction and Pleasure as measured by International Index of Erectile Function - Overall Satisfaction Subscale

    (Rosen, Riley, Wagner, Osterloh, Kirkpatrick, \& Mishra, 1997), which measures sexual satisfaction. 2-item questionnaire

    Time frame: Change from baseline to four months post-treatment (22 weeks)

  13. Self-reported Sexual Pleasure as measured by an investigator-created Questionnaire

    2-item self report questionnaire on a 5-point scale assessing physical and emotional sexual pleasure.

    Time frame: Change from baseline to immediately post treatment (6 weeks)

  14. Self-reported Sexual Pleasure as measured by an investigator-created Questionnaire

    2-item self report questionnaire on a 5-point scale assessing physical and emotional sexual pleasure.

    Time frame: Change from baseline to one month post-treatment (10 weeks)

  15. Self-reported Sexual Pleasure as measured by an investigator-created Questionnaire

    2-item self report questionnaire on a 5-point scale assessing physical and emotional sexual pleasure.

    Time frame: Change from baseline to four months post-treatment (22 weeks)

Secondary outcomes

  1. Anxiety Symptoms as measured by Generalized Anxiety Disorder-7

    (Spitzer, Kroenke, Williams, \& Lowe, 2006),7-item questionnaire

    Time frame: Change from baseline to immediately post treatment (6 weeks)

  2. Anxiety Symptoms as measured by Generalized Anxiety Disorder-7

    (Spitzer, Kroenke, Williams, \& Lowe, 2006), 7-item questionnaire

    Time frame: Change from baseline to one month post-treatment (10 weeks)

  3. Anxiety Symptoms as measured by Generalized Anxiety Disorder-7

    (Spitzer, Kroenke, Williams, \& Lowe, 2006), 7-item questionnaire

    Time frame: Change from baseline to four months post-treatment (22 weeks)

  4. Degree of Mindfulness as measured by the Five Facet Mindfulness Questionnaire-15

    (Baer, Carmody, Hunsinger, 2012; Gu, Strauss, Crane, Barnhofer, Karl, Cavanagh, \& Kuyken, 2016),15-item questionnaire

    Time frame: Change from baseline to immediately post treatment (6 weeks)

  5. Degree of Mindfulness as measured by the Five Facet Mindfulness Questionnaire-15

    (Baer, Carmody, Hunsinger, 2012; Gu, Strauss, Crane, Barnhofer, Karl, Cavanagh, \& Kuyken, 2016),15-item questionnaire

    Time frame: Change from baseline to one month post-treatment (10 weeks)

  6. Degree of Mindfulness as measured by the Five Facet Mindfulness Questionnaire-15

    (Baer, Carmody, Hunsinger, 2012; Gu, Strauss, Crane, Barnhofer, Karl, Cavanagh, \& Kuyken, 2016),15-item questionnaire

    Time frame: Change from baseline to four months post-treatment (22 weeks)

  7. Non-attachment mindfulness skill as measured by Nonattachment Scale-7

    (Sahdra, Ciarrochi, Parker, Marshall, \& Heaven, 2015) Non-attachment is a specific facet of mindfulness measured by this 7-item questionnaire

    Time frame: Change from baseline to immediately post treatment (6 weeks)

  8. Non-attachment mindfulness skill as measured by Nonattachment Scale-7

    (Sahdra, Ciarrochi, Parker, Marshall, \& Heaven, 2015) Non-attachment is a specific facet of mindfulness measured by this 7-item questionnaire

    Time frame: Change from baseline to one month post-treatment (10 weeks)

  9. Non-attachment mindfulness skill as measured by Nonattachment Scale-7

    (Sahdra, Ciarrochi, Parker, Marshall, \& Heaven, 2015) Non-attachment is a specific facet of mindfulness measured by this 7-item questionnaire

    Time frame: Change from baseline to four months post-treatment (22 weeks)

  10. Relationship satisfaction as measured by Relationship Assessment Scale

    (Hendrick, 1988) 7-item questionnaire

    Time frame: Change from baseline to immediately post treatment (6 weeks)

  11. Relationship satisfaction as measured by Relationship Assessment Scale

    (Hendrick, 1988) 7-item questionnaire

    Time frame: Change from baseline to one month post-treatment (10 weeks)

  12. Relationship satisfaction as measured by Relationship Assessment Scale

    (Hendrick, 1988)7-item questionnaire

    Time frame: Change from baseline to four months post-treatment (22 weeks)

Other outcomes

  1. Patient Satisfaction towards therapy group and Self-reported Impact on Quality of Sexual Life as measured by Patient Global Impression of Change Scale - Revised

    (adapted from Hurst \& Bolton, 2004) This is a single self-report question on participants overall satisfaction from and impact from the treatment group

    Time frame: Change from baseline to immediately post treatment (6 weeks)

  2. Patient Satisfaction towards therapy group and Self-reported Impact on Quality of Sexual Life as measured by Patient Global Impression of Change Scale - Revised

    (adapted from Hurst \& Bolton, 2004). This is a single self-report question on participants overall satisfaction from and impact from the treatment group

    Time frame: Change from baseline to one month post-treatment (10 weeks)

  3. Patient Satisfaction towards therapy group and Self-reported Impact on Quality of Sexual Life as measured by Patient Global Impression of Change Scale - Revised

    (adapted from Hurst \& Bolton, 2004) This is a single self-report question on participants overall satisfaction from and impact from the treatment group

    Time frame: Change from baseline to four months post-treatment (22 weeks)

  4. PDE5 inhibitor Medication Use

    As measured by self-report questions asking men about their use of PDE5 inhibitor medications to erectile functioning, and their perception of these medications usefulness

    Time frame: Change from baseline to immediately post treatment (6 weeks)

  5. PDE5 inhibitor Medication Use

    As measured by self-report questions asking men about their use of PDE5 inhibitor medications to erectile functioning, and their perception of these medications usefulness

    Time frame: Change from baseline to one month post-treatment (10 weeks)

  6. PDE5 inhibitor Medication Use

    As measured by self-report questions asking men about their use of PDE5 inhibitor medications to erectile functioning, and their perception of these medications usefulness

    Time frame: Change from baseline to four months post-treatment (22 weeks)

  7. Mindfulness and Sexual Activities Practice as measured by investigator-created questionnaire

    Daily log of types of activities and minutes practiced

    Time frame: Change from baseline to immediately post treatment (6 weeks)

  8. Mindfulness and Sexual Activities Practice as measured by investigator-created questionnaire

    Daily log of types of activities and minutes practiced

    Time frame: Change from baseline to one month post-treatment (10 weeks)

  9. Mindfulness and Sexual Activities Practice as measured by investigator-created questionnaire

    Daily log of types of activities and minutes practiced

    Time frame: Change from baseline to four months post-treatment (22 weeks)

07

Study locations

1 of 1 sites recruiting
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
    Recruiting
    • Miriam Driscoll, MD · Contact
08

References and documents

Publications

  • Bossio JA, Basson R, Driscoll M, Correia S, Brotto LA. Mindfulness-Based Group Therapy for Men With Situational Erectile Dysfunction: A Mixed-Methods Feasibility Analysis and Pilot Study. J Sex Med. 2018 Oct;15(10):1478-1490. doi: 10.1016/j.jsxm.2018.08.013. PubMed 30297094 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2020 (actual). Primary completion is estimated for Dec 2024, 56 months after the start.

Of 115 non-industry interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 56 months is above that.

Counting every sponsor, half of 137 studies reached it within 32 months; a quarter within 14 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2019
First posted
Apr 10, 2020
StartActual
Apr 14, 2020
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Oct 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04341025
Lead sponsor
Vancouver Coastal Health
Responsible party
Miriam Driscoll (PI, Vancouver Coastal Health) — Principal investigator
First posted
Apr 10, 2020
Start date
Apr 14, 2020
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Oct 19, 2022

Study contacts

Shauna Correia, MD
Contact
shauna.correia@vch.ca
604-875-4705
Miriam Driscoll, MD
Contact
miriam.driscoll@vch.ca
604-875-4705
Miriam Driscoll, MD
principal investigator · UBC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion